BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Hi Angus
Looks like you are firmly in the US market.
Looks like it is going well
zAngus
⋅
@gheli, I'm trading the globe :) Just that the US market is opening next so its what Im looking at right now. Im still in a couple of Aus stocks, but the ASX in general for me isnt performing as well as US. Japan / Tokyo is my current favourite market at the moment. Seems to stay out of the trade wars and corona dramas for whatever reason - or maybe the news just isnt covering them as much.
zAngus
⋅
@Angusmck, the other thing is I do also update charts for ASX stocks, but I always add to the previous post rather than start a new one so probably makes it look like I havent been adding or updating ASX stocks. eg see for example.
gheli
⋅
@Angusmck, All good mate.
I appreciate your posts
I'm ASX, but maybe looking to US as well
Also learning fx
Thanks for your good info
Looks like you are firmly in the US market.
Looks like it is going well